Holen Sie sich die Stockscreener-App
69.83
0.05%
0.035
Schlusskurs vom Vortag:
$69.80
Offen:
$69.775
24-Stunden-Volumen:
6.32M
Relative Volume:
1.26
Marktkapitalisierung:
$10.19B
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-19.63
EPS:
-3.5569
Netto-Cashflow:
$-502.70M
1W Leistung:
-0.14%
1M Leistung:
+48.59%
6M Leistung:
+116.88%
1J Leistung:
+55.81%
1-Tages-Spanne:
$69.76
$69.87
1-Wochen-Bereich:
$69.50
$69.96
52-Wochen-Spanne:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
69.83 | 10.25B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Visual analytics tools that track Avidity Biosciences Inc. performanceRate Cut & Consistent Growth Stock Picks - newser.com
Real time alert setup for Avidity Biosciences Inc. performanceWeekly Market Outlook & Technical Confirmation Trade Alerts - newser.com
Short interest data insights for Avidity Biosciences Inc.Portfolio Update Summary & AI Forecasted Stock Moves - newser.com
Can Avidity Biosciences Inc. stock deliver sustainable ROEEarnings Risk Summary & Expert Curated Trade Ideas - newser.com
Is Avidity Biosciences Inc. showing signs of accumulation2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsGap Up & Low Risk High Win Rate Stock Picks - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsMarket Activity Report & Entry Point Confirmation Signals - newser.com
Applying Wyckoff theory to Avidity Biosciences Inc. stockWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Forecasting Avidity Biosciences Inc. price range with options dataJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysJuly 2025 Institutional & Technical Buy Zone Confirmation - newser.com
Using AI based signals to follow Avidity Biosciences Inc.July 2025 Fed Impact & Free Long-Term Investment Growth Plans - newser.com
Will Avidity Biosciences Inc. stock sustain high P E ratiosJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock price2025 Historical Comparison & Reliable Price Breakout Signals - newser.com
How Avidity Biosciences Inc. stock performs in weak economyJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - newser.com
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Why Avidity Biosciences Inc. stock attracts global investorsMarket Trend Report & Capital Protection Trade Alerts - newser.com
Why Avidity Biosciences Inc. stock is popular among millennialsWeekly Trend Summary & Community Driven Trade Alerts - newser.com
Will Avidity Biosciences Inc. stock deliver long term returnsMarket Trend Review & Smart Allocation Stock Reports - newser.com
How Avidity Biosciences Inc. stock benefits from strong dollarJuly 2025 Price Swings & High Accuracy Trade Signal Alerts - newser.com
Earnings visualization tools for Avidity Biosciences Inc.Portfolio Growth Summary & Real-Time Sentiment Analysis - newser.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Insider Monkey
Can Avidity Biosciences Inc. stock beat market expectations this quarterJuly 2025 Outlook & AI Optimized Trade Strategies - newser.com
Can Avidity Biosciences Inc. stock surprise with earnings upsideJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge - Yahoo Finance
10 Stocks With Easy 20-40% Gains - Insider Monkey
Is Avidity Biosciences Inc. stock ready for breakout2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
What momentum shifts mean for Avidity Biosciences Inc.Portfolio Performance Report & High Return Trade Guides - newser.com
Will a bounce in Avidity Biosciences Inc. offer an exitWeekly Gains Report & Weekly Setup with High ROI Potential - newser.com
Avidity Biosciences, Inc. (RNA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Best Pharmaceutical Stocks To Follow TodayOctober 27th - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Lowered to "Hold" Rating by Wolfe Research - MarketBeat
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avidity Biosciences Inc-Aktie (RNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):